Changes in Hong Kong stocks | Rongchang Biotech (09995) rose nearly 5%, 10 studies unveiled, ESMO institutions are optimistic about the acceleration of its overseas expansion

The Zhitong Finance App learned that Rongchang Biotech (09995) rose nearly 5%. As of press release, it had risen 4.81% to HK$96.95, with a turnover of HK$706 million.

According to the news, the 2025 European Society of Medical Oncology (ESMO) Annual Meeting was held in Berlin, Germany from October 17 to 21, local time. At this year's annual conference, 10 Rongchang Biotech research projects were showcased. Among them, the results of the RC48-C016III study data for first-line treatment of urothelial carcinoma with verdicitumab were announced for the first time at the General Assembly President's Forum, and the full text was simultaneously published online in the “New England Journal of Medicine” (NEJM). Additionally, data from the Chinese Phase III clinical study of titacipr for the treatment of IgA nephropathy will be presented in the form of a “Latest Breakthrough Oral Report (Late-Breaking Oral)” at the 2025 American Society of Nephrology (ASN) Annual Meeting. The conference will be held in Houston, USA from November 5 to 9.

Huatai Securities believes that intensive data reading fully confirms the global competitiveness of the company's pipeline and is expected to accelerate its overseas expansion: 1) the overseas 1LUCIII phase of verdicitumab is progressing steadily, and the bank expects 2LUC indications to be BLA in early 2026; 2) RC148 has received CDEBTD, overseas phase I/II clinical approval has been approved by the FDA, showing potential to go overseas; 3) Taitaxip MG is successfully enrolled in phase III of the global phase III program, and PSS is expected to become the next key indication. Maintain “buy-in.”